DNA/Gene Microarray MarketSize and Trends

The global DNA/gene microarray market is estimated to be valued at US$ 4.24 Billion in 2023 and is expected to exhibit a CAGR of 12.9% during the forecast period (2023-2030).

Figure 1. Global DNA/Gene Microarray Market Share (%), By Type, 2023

Figure 2. Global DNA/Gene Microarray Market Share (%), By Region, 2023

Global DNA/Gene Microarray Market Segmentation:

The global DNA/gene microarray market report is segmented into by type, by application, by end user and by region.

By type, the market is segmented into oligonucleotide DNA microarrays and complementary DNA microarrays. Out of which, the oligonucleotide DNA microarrays segment is expected to hold a dominant position in the global DNA/gene microarray market during the forecast period, and this is attributed to the rising prevalence of cancer cases globally.
By application, the market is segmented into genomics, proteomics, agricultural biology, environment, drug research and development, cancer/oncology, and others (SNP analysis, etc.). Out of which, the genomics segment is expected to dominate the market over the forecast period, and this is attributed to the adoption of various growth strategies, such as product launches, partnership strategies, and others, by the market players.
By end user, the market is segmented into biopharmaceutical and pharmaceutical companies, diagnostic laboratories, research laboratories, and others (academic institutes and others). The diagnostic laboratories segment is expected to dominate the market over the forecast period, and this is due to the increasing demand for diagnostic laboratories for the diagnosis of various diseases such as cancer and others.
Based on region, the market is segmented into North America, Latin America. Europe, Asia Pacific, Middle East and Africa. Out of which, the North America region is expected to dominate the market over the forecast period, and this is due to the increasing product approval from the U.S FDA (Food and Drug Administration) by the market players in this region.
Among all the segmentations, the type segment has the highest potential due to the increasing inorganic growth strategies, such as acquisitions and others, by the key market players. For instance, in September 2021, SCHOTT MINIFAB, a subsidiary of SCHOTT, a technology company that develops and manufactures microfluidic devices for point-of-care and life sciences consumables, announced that they had acquired Applied Microarrays Inc. (AMI), a U.S.-based company, which will further help the company strengthens its single-source contract manufacturing solution in the North America Region.

Global DNA/Gene Microarray Market- Cross Sectional Analysis:

The rising number of new product launches in the North America region, is expected to propel market growth over the forecast period. For instance, In April 2021, the National Center for Biotechnology Information announced the introduction of CovidArray, a microarray-based test to detect COVID-19 markers N1 and N2 in nasopharyngeal swab samples. The universal microarray can detect the genotypes of six mutated bases related to COVID-19.

Global DNA/Gene Microarray Market - Key Players

Major players operating in the global DNA/gene microarray market include Affymetrix, Inc., Illumina, Inc., Agilent Technologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix Technology Inc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC, Microarrays Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Perkin Elmer, Inc., PathogenDx, Inc., Twist Bioscience Corporation, Arraylt Corporation, Molecular Device, LLC and Raybiotech Inc.

Global DNA/Gene Microarray Market: Key Trend

Increasing fundings by the market players: Increasing growth strategies by the market players, such as funding and others, are expected to drive growth of the market over the forecast period. For instance, in June 2022, Ariceum Therapeutics, a private clinical-stage radiopharmaceutical company, announced funding of US$ 25 million in Series A to enhance its lead asset, Satoreotide, for the diagnosis of low- and high-neuroendocrine cancer.